Zhang Financial LLC grew its holdings in Tiziana Life Sciences Ltd (NASDAQ:TLSA Free Report) by 61.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities...

Share to Feed

Tiziana Life Sciences initiates multi-center Phase 2a clinical trial of intranasal foralumab for na-SPMSProactive Investors - UK • 5 days ago

Tiziana Life Sciences initiates multi-center Phase 2a clinical trial of intranasal foralumab for na-SPMS...

Tiziana Life Sciences initiates Phase 2a trial of intranasal foralumabThe Fly • 5 days ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple SclerosisGlobe Newswire • 5 days ago

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ( Tiziana or the Company ), a biotechnology company developing breakthrough immunomodulation therapies via...

Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceGlobe Newswire • 23 days ago

NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ( Tiziana or the Company ), a biotechnology company developing breakthrough immunomodulation therapies via...

Tiziana Life Sciences announces publication on intranasal foralumabThe Fly • 25 days ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Study Validating MoA of Intranasal Foralumab in Alzheimer s Disease Published in the Prestigious Journal PNAS, Following FDA IND ClearanceGlobe Newswire • 25 days ago

The authors conclude that nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer s disease (AD) FDA has cleared the IND for intranasal...

Tiziana Life Sciences highlights publication of promising Alzheimer s study resultsProactive Investors - UK • 26 days ago

Tiziana Life Sciences highlights publication of promising Alzheimer s study results...

Tiziana Life Sciences announces Foralumab presentation at ISNI meetingThe Fly • about 1 month ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of NeuroimmunologyGlobe Newswire • about 1 month ago

NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ( Tiziana or the Company ), a biotechnology company developing breakthrough immunomodulation therapies via...

Home
Symbol
TLSA
News

3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.

Latest TLSA News

View

Zhang Financial LLC Acquires 17,100 Shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA)

Ticker Report • 5 days ago

Tiziana Life Sciences initiates multi-center Phase 2a clinical trial of intranasal foralumab for na-SPMS

Proactive Investors - UK • 5 days ago

Tiziana Life Sciences initiates Phase 2a trial of intranasal foralumab

The Fly • 5 days ago

Join the conversation.This is where all the magic happens.